Name: FDA Approves Eli Lilly’s Zepbound Drug For Weight Loss
Uploaded: 2023-11-08T21:15:12.966
Duration: 4 min 11 s
Description: The FDA approves Eli Lilly’s (LLY) Tirzepatide drug for weight loss. The weight loss drug, Zepbound, it to be available by the end of 2023 and a one-month supply is to cost about $1,060. Zepbound should compete against Novo Nordisk’s Weogvy and Ozempic. Jenny Horne weighs in on this story. Tune in to find out more about the stock market today.

Join host Ben Lichtenstein as he examines the latest developments in the futures markets live. This show uses charts and technical analysis to break down commodities trading and explore trading trends. Guest contributors also make appearances, sharing their insights on futures trading as it relates to market events.

Futures

Kick off the trading day with Oliver Renick as he ties big macro concepts together with stock-specific analysis and trading strategies. This program cuts through the noise and political bias, while helping viewers understand the economy's relationship with markets through numbers, logic and in-depth interviews with fund managers, ETF providers and options traders.&nbsp;

Morning Trade Live

After the dust settles from the opening bell,&nbsp;Trading 360&nbsp;with Nicole Petallides&nbsp;features Wall Street’s best traders, analysts and technicians to break down sectors and stocks moving markets. Trading 360&nbsp;with Nicole Petallides focuses on disruptive companies and new technologies driving market&nbsp;headlines while providing investors a 360 degree actionable approach to trading.

Trading 360

Hosts Tom White and Kevin Hincks break down the market; providing in-depth insights for Intermediate to Advanced Traders on how to interpret current market activity. Technical market specialists, analysts and outside guests join the program, giving their take on different markets, sectors, and various products.

Fast Market

The future of trading is here on Next Gen Investing. Alex Coffey and Jenny Horne take viewers through the markets from a unique perspective to help new investors pursue their financial goals. Next Gen Investing will explore various trading strategies while highlighting trending names and under the radar stocks in the market, while walking investors through real-time example trades.

Next Gen Investing

The Watch List with Nicole Petallides offers investors a midday look at the most relevant stocks, sectors and commodities. Petallides hosts a panel of experts ranging from industry-leading CEOs, analysts and Wall Street influencers to discuss pressing topics moving the market in real-time. The Watch List provides viewers with a midpoint status update for the end of the trading day and beyond.

The Watch List

Wrap up your trading day with Oliver Renick as he gives a live recap of the day's top stories and market movers, then look ahead to tomorrow's expectations and upcoming events.

Market On Close

Market Overtime takes a break from the day-to-day news cycle and explores global financial trends with veteran investors and leading market minds. The show is a conversation looking at what is driving headlines globally, and what these trends mean for markets, the economy, and your financial future. What are the stories that will impact your portfolio for the next year, next decade and beyond? Tune in to Market Overtime to get a new perspective on investing.

Market Overtime

Instead of sitting on the sidelines, take control of your financial future by watching Your First Trade. Host Ben Watson, Sr. Manager, Education Coach&nbsp;takes you on an educational journey where you can discover fundamental trading concepts and how to navigate the thinkorswim platform from Charles Schwab &amp; Co., Inc, member FINRA/SIPC, a subsidiary of The Charles Schwab Corporation. Your First Trade program content is presented by Charles Schwab &amp; Co., Inc. a broker/dealer, for educational purposes only.

Your First Trade

Season 1

Season 2

Daily insights for every investor

Get the Market Minute

The FDA approves Eli Lilly’s (LLY) Tirzepatide drug for weight loss. The weight loss drug, Zepbound, it to be available by the end of 2023 and a one-month supply is to cost about $1,060. Zepbound should compete against Novo Nordisk’s Weogvy and Ozempic. Jenny Horne weighs in on this story. Tune in to find out more about the stock market today.

FDA Approves Eli Lilly’s Zepbound Drug For Weight Loss

Expert commentary about top moving stocks, sectors, and commodities, along with CEO and analyst interviews.